Fusen Pharmaceutical surges 14% in Hong Kong tradingMarket Movers·Oct 29, 2026 at 07:23 AM01652-2.47%
Fusen Pharmaceutical climbs 11% in Hong Kong tradingMarket Movers·Oct 26, 2026 at 06:46 AM01652-2.47%
Fusen Pharmaceutical Extends Completion Date for Deemed Equity DisposalTip Ranks·Oct 8, 2026 at 12:12 PM01652-2.47%
Hong Kong Small-Caps Rewrite Survival Playbook Amid Regulatory OnslaughtGlobal Report·Sep 29, 2026 at 09:14 AM02076+3.05%01071+0.69%
Fusen Pharma FY26 H1 net loss narrows 40.9% to RMB 13.67 million; revenue rises 2.5% to RMB 114.06 millionPUBT·Aug 31, 2026 at 02:53 PM01652-2.47%
Fusen Pharma board to review interim results, consider dividendPUBT·Aug 19, 2026 at 10:22 AM01652-2.47%
Fusen Pharmaceutical Wins China Approval for New Doxazosin Extended-Release TabletsTip Ranks·Jul 10, 2026 at 12:38 PM01652-2.47%
Fusen Pharma says China regulator clears doxazosin mesylate extended-release tablets for marketingPUBT·Jul 10, 2026 at 12:10 PM01652-2.47%
Fusen Pharma shareholders back RMB 300 million target unit capital increase plan at EGMPUBT·Jul 9, 2026 at 08:47 AM01652-2.47%